- CRH chief executive tops list of deals
- Ex-GSK director sells stock awarded in 2020
- Redde Northgate chief also cashes in
In a quiet week for director deals one or two trades stood out, firstly the decision by Albert Manifold, chief executive of building materials firm CRH (CRH), to sell 58,346 shares at €51.48 last week, raising €3 million in proceeds.
CRH’s Dublin-listed shares are up 43% this year, recently hitting a multi-year high of €54, while its London quote is due to cease on 25 September after the firm moves its primary listing to New York.
The firm argues the move to Wall Street ‘will bring increased commercial, operational and acquisition opportunities for our business, further accelerating our successful integrated solutions strategy and delivering even higher levels of profitability, returns and cash for our shareholders’.
FORMER PHARMA EXEC CASHES IN OPTIONS
Meanwhile, former GSK (GSK) executive Dr Hal Barron to exercise some of the nil-cost options from his 2020 pay award and offload them in the market.
Latest Issue
- How leading fund managers identify genuine growth opportunities. Examining the criteria applied by the experts and identifying two stocks which could have real long-term potential.
- Plus, what does it mean when a company has a wide moat, the latest on Unilever’s big shake-up and Steven Frazer’s updated view on PayPal.
- Read about Imperial Brands shares being at five-year highs, why Lifetime ISA house price limits are putting the squeeze on first-time buyers and a revamp of popular investment trust Edinburgh Worldwide.
- Investment ideas include a value-focused fund and a conglomerate with a leading retail brand and there are articles on JD Sports, On The Beach, Salesforce and much, much more.
Barron, who until March 2022 was chief scientific officer and president of R&D (research and development) at GSK, cashed in 155,206 ADS (American depository shares) at an average price of $17.31 to net a comfortable $2.67 million.
After leaving the UK firm in March last year, Barron took on the role of chief executive and chairman at US cellular technology company Altos Labs.
